The UAE Cabinet has approved the board of directors of the Emirates Drug Establishment, which will be chaired by Dr. Thani Al Zeyoudi, Minister of State for Foreign Trade.
Dr. Fatima Al Kaabi has been assigned to carry out the duties of director general of the newly-formed entity.
The board includes Dr. Maha Taysir Barakat, Assistant Minister for Medical Affairs & Life Sciences at Ministry of Foreign Affairs as the Vice Chairman; Dr. Essa Abdulfattah Kazim, Governor of the Dubai International Financial Centre; Badr Al Olama, Acting Director General of the Abu Dhabi Investment Office; Dr. Amer Ahmad Sharif, CEO of Dubai Academic Health Corporation; Dr. Farhan Malik, Group CEO of PureHealth; Professor Christopher Evans, scientific researcher and businessman; in addition to a youth representative nominated by the General Secretariat of the Cabinet.
The Emirates Drug Establishment aims to strengthen the country’s position as a global hub for pharmaceutical and medical industries, promote research and development in this sector and provide a nurturing environment for pharmaceutical investments.
The entity will also contribute to enhancing the production, development and export of high-quality medical and pharmaceutical products, as well as ensuring the availability, effectiveness and safety of these products.
UAE Cabinet approves the formation of the Board of Directors of Emirates Drug Establishment
— UAEGOV (@UAEmediaoffice) December 7, 2023
Dr. Fatima Alkaabi to carry out the duties of director general of the establishment pic.twitter.com/U7JrnXeXN3
H.H. Sheikh Mohammed issues law on Dubai antiquities, archeological sites
UAE calls for action as Iran continues to violate UN resolution
Eid Al Adha holiday: Emirates issues peak travel advisory
H.H. Sheikh Hamdan approves second AED 1.5bn economic incentives package
UAE minister affirms prospering economic model amidst regional developments
